Publicacións en colaboración con investigadores/as de Institute Catalá Oncología (20)

2024

  1. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

    Lung Cancer, Vol. 190

  2. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

  3. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk

    Lung Cancer, Vol. 195

2023

  1. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

  2. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

    Translational Lung Cancer Research, Vol. 12, Núm. 10, pp. 2113-2128

2020

  1. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

    Translational Lung Cancer Research, Vol. 9, Núm. 4, pp. 1074-1083

  2. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation

    Cancer Epidemiology, Vol. 67

2019

  1. Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)

    Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475

2018

  1. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536

  2. LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38

2017

  1. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions

    Annals of Oncology, Vol. 28, Núm. 9, pp. 2248-2255

2016

  1. 149P: The role of CTCs and cfDNA for diagnosis and monitoring of EGFR mutations in advanced NSCLC patients

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S123

2014

  1. Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility

    Clinical and Translational Oncology, Vol. 16, Núm. 1, pp. 107-112

2010

  1. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

    Lung Cancer, Vol. 68, Núm. 3, pp. 491-497

  2. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?

    Lung Cancer, Vol. 68, Núm. 3, pp. 415-419

2008

  1. Pharmacogenetics in lung cancer for the lay doctor

    Targeted Oncology, Vol. 3, Núm. 3, pp. 161-171

2006

  1. Pharmacogenomics and gemcitabine

    Annals of Oncology, Vol. 17, Núm. SUPPL. 5

  2. Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 17, Núm. 4, pp. 668-675

2005

  1. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 16, Núm. 7, pp. 1081-1086

2002

  1. Low ERRC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer

    Clinical Cancer Research, Vol. 8, Núm. 7, pp. 2286-2291